Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE

Diabetes care22 May 2013Cited by 200 (Europe PMC)

PMID23698396PMCIDPMC3781502DOI10.2337/dc12-2709PepBankPUB-23698396

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with diabetes on metformin, HbA1c fell by 0.96% with exenatide versus 0.79% with lixisenatide, and lixisenatide met the noninferiority margin.
In plain wordsIn adults with diabetes, HbA1c fell with both drugs, and lixisenatide met noninferiority criteria versus exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change
Study
n = 634
Comparator
Lixisenatide once daily
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Measurements
HbA1c least squares mean change
−0.96%
exenatide
HbA1c least squares mean change
−0.79%
lixisenatide
HbA1c treatment difference (lixisenatide versus exenatide)
0.17%
lixisenatide versus exenatide
Source sentences
Summary
The least squares mean change was -0.79% (mean decrease 7.97 to 7.17%) for lixisenatide versus -0.96% (mean decrease 7.96 to 7.01%) for exenatide, and treatment difference was 0.17% (95% CI, 0.033-0.297), meeting a predefined noninferiority upper CI margin of 0.4%.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary objective was a noninferiority assessment of lixisenatide versus exenatide in HbA1c change from baseline to week 24.
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839601
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, lixisenatide was noninferior to exenatide for HbA1c reduction: -0.79% versus -0.96%, difference 0.17% (95% CI 0.033-0.297).
In plain wordsIn adults with diabetes on metformin, lixisenatide met the trial's noninferiority criterion despite a numerically smaller HbA1c reduction than exenatide.
Peptide
Lixisenatide
Outcome
IncreaseHbA1c change and noninferiority
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Measurements
Least squares mean HbA1c change
−0.79%
lixisenatide, baseline to week 24
Least squares mean HbA1c change
−0.96%
exenatide, baseline to week 24
Baseline HbA1c
7.97%
lixisenatide
Final HbA1c
7.17%
lixisenatide
Baseline HbA1c
7.96%
exenatide
Final HbA1c
7.01%
exenatide
Treatment difference in HbA1c change (lixisenatide minus exenatide)
0.17%
lixisenatide vs exenatide
95% CI of treatment difference
0.033 to 0.297%
lixisenatide vs exenatide
1 more measurement in the study.
Source sentences
Summary
The least squares mean change was -0.79% (mean decrease 7.97 to 7.17%) for lixisenatide versus -0.96% (mean decrease 7.96 to 7.01%) for exenatide, and treatment difference was 0.17% (95% CI, 0.033-0.297), meeting a predefined noninferiority upper CI margin of 0.4%.
2 context sentences(design, population, supporting numbers)
Summary · context
Lixisenatide once daily demonstrated noninferiority in HbA1c reduction versus exenatide twice daily.
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839611
03HumanRandomized controlled trialEfficacy outcome
In adults with diabetes, HbA1c below 7.0% responder rates were comparable with exenatide and lixisenatide.
In plain wordsIn adults with diabetes, similar proportions reached HbA1c below 7.0% with exenatide and lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c below target
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Responder rate (HbA1c<7.0%) and improvements in fasting plasma glucose were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839602
04HumanRandomized controlled trialEfficacy outcome
In adults with diabetes, fasting plasma glucose improvements were comparable with exenatide and lixisenatide.
In plain wordsIn adults with diabetes, fasting glucose improvements were similar with exenatide and lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting plasma glucose
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Responder rate (HbA1c<7.0%) and improvements in fasting plasma glucose were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839603
05HumanRandomized controlled trialEfficacy outcome
In adults with diabetes, weight fell from 96.7 to 92.9 kg with exenatide, while lixisenatide also reduced weight.
In plain wordsIn adults with diabetes, weight fell with exenatide and with lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 634
Outcome group
Body weight · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Measurements
Body weight
96.7 kg
exenatide baseline
Body weight
92.9 kg
exenatide follow-up
Source sentences
Summary
Both agents induced weight loss (from 94.5 to 91.7 kg and from 96.7 to 92.9 kg with lixisenatide and exenatide, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839604
06HumanRandomized controlled trialSafety outcome
In adults with diabetes, adverse event incidence was similar with exenatide and lixisenatide.
In plain wordsIn adults with diabetes, adverse event rates were similar with exenatide and lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdverse events
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Adverse events · Whole body
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Incidence of adverse events (AEs) was similar for lixisenatide and exenatide, as was incidence of serious AEs (2.8 and 2.2%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839605
07HumanRandomized controlled trialSafety outcome
In adults with diabetes, serious adverse events occurred in 2.2% with exenatide versus 2.8% with lixisenatide, with similar incidence.
In plain wordsIn adults with diabetes, serious adverse event rates were similar with exenatide and lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSerious adverse events
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Adverse events · Whole body
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Measurements
Serious adverse event incidence
2.2%
exenatide
Serious adverse event incidence
2.8%
lixisenatide
Source sentences
Summary
Incidence of adverse events (AEs) was similar for lixisenatide and exenatide, as was incidence of serious AEs (2.8 and 2.2%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839606
08HumanRandomized controlled trialSafety outcome
In adults with diabetes, adverse events caused discontinuation in 41 exenatide patients versus 33 lixisenatide patients.
In plain wordsIn adults with diabetes, more patients stopped exenatide than lixisenatide because of adverse events.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDiscontinuations due to adverse events
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Adverse events · Whole body
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Measurements
Discontinuation due to adverse events
13%
exenatide, 41 patients
Discontinuation due to adverse events
10.4%
lixisenatide, 33 patients
Source sentences
Summary
Discontinuations attributable to AEs occurred in 33 lixisenatide (10.4%) and 41 exenatide (13.0%) patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839607
09HumanRandomized controlled trialSafety outcome
In adults with diabetes, symptomatic hypoglycemia occurred in 7.9% with exenatide versus 2.5% with lixisenatide.
In plain wordsIn adults with diabetes, symptomatic low blood sugar was more frequent with exenatide than lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSymptomatic hypoglycemia
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Measurements
Symptomatic hypoglycemia incidence
7.9%
exenatide
Symptomatic hypoglycemia incidence
2.5%
lixisenatide
Source sentences
Summary
In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P<0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839608
10HumanRandomized controlled trialSafety outcome
In adults with diabetes, gastrointestinal events were more frequent with exenatide than lixisenatide.
In plain wordsIn adults with diabetes, digestive adverse events were more frequent with exenatide than lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGastrointestinal events
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Source sentences
Summary
In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P<0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839609
11HumanRandomized controlled trialSafety outcome
In adults with diabetes, nausea occurred in 35.1% with exenatide versus 24.5% with lixisenatide.
In plain wordsIn adults with diabetes, nausea was more frequent with exenatide than lixisenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea
Study
n = 634
Comparator
Lixisenatide once daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 μg twice daily · 24 weeksAs given in this study (human).
Measurements
Nausea incidence
35.1%
exenatide
Nausea incidence
24.5%
lixisenatide
Source sentences
Summary
In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P<0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839610
12HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, HbA1c <7.0% responder rates were comparable with lixisenatide and exenatide.
In plain wordsIn adults with diabetes on metformin, similar proportions reached the HbA1c target with lixisenatide and exenatide.
Peptide
Lixisenatide
Outcome
No significant changeHbA1c below 7.0% responder rate
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Responder rate (HbA1c<7.0%) and improvements in fasting plasma glucose were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839612
13HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, fasting glucose improvements were comparable with lixisenatide and exenatide.
In plain wordsIn adults with diabetes on metformin, fasting glucose improved similarly with lixisenatide and exenatide.
Peptide
Lixisenatide
Outcome
No significant changeFasting plasma glucose improvement
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
Responder rate (HbA1c<7.0%) and improvements in fasting plasma glucose were comparable.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839613
14HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, overall adverse event incidence was similar with lixisenatide and exenatide, as was serious adverse event incidence (2.8% vs 2.2%).
In plain wordsIn adults with diabetes on metformin, adverse events, including serious ones, occurred at similar rates with lixisenatide and exenatide.
Peptide
Lixisenatide
Outcome
No significant changeOverall and serious adverse events
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Adverse events · Whole body
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Measurements
Incidence of serious adverse events
2.8%
lixisenatide
Incidence of serious adverse events
2.2%
exenatide
Source sentences
Summary
Incidence of adverse events (AEs) was similar for lixisenatide and exenatide, as was incidence of serious AEs (2.8 and 2.2%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839615
15HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, serious adverse events occurred in 2.8% with lixisenatide versus 2.2% with exenatide, described as similar.
In plain wordsIn adults with diabetes on metformin, serious adverse events were numerically more frequent with lixisenatide than exenatide, but described as similar.
Peptide
Lixisenatide
Outcome
IncreaseSerious adverse events
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Measurements
Serious adverse events incidence
2.8%
lixisenatide
Serious adverse events incidence
2.2%
exenatide
Source sentences
Summary
Incidence of adverse events (AEs) was similar for lixisenatide and exenatide, as was incidence of serious AEs (2.8 and 2.2%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839616
16HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, adverse events caused discontinuation in 33 lixisenatide patients (10.4%) versus 41 exenatide patients (13.0%).
In plain wordsIn adults with diabetes on metformin, fewer stopped treatment because of adverse events with lixisenatide than exenatide.
Peptide
Lixisenatide
Outcome
DecreaseAdverse event discontinuations
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Measurements
Discontinuations due to adverse events
33 participants
lixisenatide
Discontinuations due to adverse events
10.4%
lixisenatide
Discontinuations due to adverse events
41 participants
exenatide
Discontinuations due to adverse events
13%
exenatide
Source sentences
Summary
Discontinuations attributable to AEs occurred in 33 lixisenatide (10.4%) and 41 exenatide (13.0%) patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839617
17HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, symptomatic hypoglycemia occurred in 2.5% with lixisenatide versus 7.9% with exenatide (P<0.05).
In plain wordsIn adults with diabetes on metformin, symptomatic low blood sugar occurred less often with lixisenatide than exenatide.
Peptide
Lixisenatide
Outcome
DecreaseSymptomatic hypoglycemia
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Measurements
Symptomatic hypoglycemia incidence
2.5%
lixisenatide
Symptomatic hypoglycemia incidence
7.9%
exenatide
P value
< 0.05
lixisenatide versus exenatide
Source sentences
Summary
In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P<0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839618
18HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, gastrointestinal events occurred less often with lixisenatide than exenatide.
In plain wordsIn adults with diabetes on metformin, gastrointestinal side effects occurred less often with lixisenatide than exenatide.
Peptide
Lixisenatide
Outcome
DecreaseGastrointestinal events
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Source sentences
Summary
In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P<0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839619
19HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, nausea occurred in 24.5% with lixisenatide versus 35.1% with exenatide (P<0.05).
In plain wordsIn adults with diabetes on metformin, nausea occurred less often with lixisenatide than exenatide.
Peptide
Lixisenatide
Outcome
DecreaseNausea
Study
n = 634
Comparator
Exenatide 10 μg twice daily
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Measurements
Nausea incidence
24.5%
lixisenatide
Nausea incidence
35.1%
exenatide
P value
< 0.05
lixisenatide versus exenatide
Source sentences
Summary
In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P<0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839620
20HumanNon-randomized trialEfficacy outcome
In adults with type 2 diabetes on metformin, body weight decreased from 94.5 to 91.7 kg with lixisenatide; with exenatide it decreased from 96.7 to 92.9 kg.
In plain wordsIn adults with diabetes on metformin, weight went down from 94.5 to 91.7 kg with lixisenatide; weight also went down with exenatide.
Peptide
Lixisenatide
Outcome
DecreaseBody weight change
Study
n = 318
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
20 μg once daily · 24 weeksAs given in this study (human).
Measurements
Body weight
94.5 kg
lixisenatide, baseline
Body weight
91.7 kg
lixisenatide, after treatment
Body weight
96.7 kg
exenatide, baseline
Body weight
92.9 kg
exenatide, after treatment
Source sentences
Summary
Both agents induced weight loss (from 94.5 to 91.7 kg and from 96.7 to 92.9 kg with lixisenatide and exenatide, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Adults with diabetes inadequately controlled (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 μg once daily (n=318) or exenatide 10 μg twice daily (n=316) in a 24-week (main period), open-label, parallel-group, multicenter study.
Report a problemFND-2369839614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00707031

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Sanofin = 639Jun 2008 to Nov 2010

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 2 Dec 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.